Barely Significant
← all excerpts

Hyperinflammation due to COVID-19 and the Targeted Use of Interleukin-1 Inhibitors.

Mediterr J Rheumatol · 2022 · PMC9450206 · PMID 36128214

Europe PMCDOI
1
hedged sentence
0.0450
closest p · 0.9× alpha
0.0450
boldest claim

The sentences

borderline significanceP=0.045actually significant
16 A phase 3 trial of anakinra in COVID-19 patients who were predominantly treated with dexamethasone revealed a survival benefit at 28 days with borderline significance (Hazard Ratio 0.45, P=0.045). 17 The beneficial effect of anakinra plus methylprednisolone at 28 days was also demonstrated in a prospective cohort study of COVID-19 patients with or without mechanical ventilation (n=120). 18 However, a trial of subcutaneous administration of anakinra in patients w

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.